A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors

Show other versions (1)

Ertumaxomab (ertu) is a bispecific, trifunctional antibody targeting Her2/neu, CD3 and the Fcγ-receptors I, IIa, and III forming a tri-cell complex between tumor cell, T cell and accessory cells.

Saved in:

Bibliographic Details
Main Authors:	Hänse, Nicole (Author) , Marmé, Frederik (Author) , Haag, Georg Martin (Author)
Format:	Article (Journal)
Language:	English
Published:	07 July 2016
In:	BMC cancer Year: 2016, Volume: 16
ISSN:	1471-2407
DOI:	10.1186/s12885-016-2449-0
Online Access:	Verlag, Volltext: http://dx.doi.org/10.1186/s12885-016-2449-0 Verlag, Volltext: https://doi.org/10.1186/s12885-016-2449-0
Author Notes:	N. Haense, A. Atmaca, C. Pauligk, K. Steinmetz, F. Marmé, G.M. Haag, M. Rieger, O.G. Ottmann, P. Ruf, H. Lindhofer and S.-E. Al-Batran

Description
Summary:	Ertumaxomab (ertu) is a bispecific, trifunctional antibody targeting Her2/neu, CD3 and the Fcγ-receptors I, IIa, and III forming a tri-cell complex between tumor cell, T cell and accessory cells.
Item Description:	Gesehen am 15.01.2019
Physical Description:	Online Resource
ISSN:	1471-2407
DOI:	10.1186/s12885-016-2449-0